Cara | $8,000,000 | (Apr 2, 2026)
Rowan(US) | $3,300,000 | (Apr 2, 2026)
Earlyasset | $2,000,000 | (Apr 2, 2026)
SAMABRIVA
France
- Amiens, Hauts-de-France
- 13/12/2023
- Unknown
- $4,313,000
Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.
- Industry Biotechnology Research
- Website https://samabriva.com/
- LinkedIn https://www.linkedin.com/company/samabriva/about/
Related People
Marina GuilletFounder
France -
Greater Nantes Metropolitan Area
Samabriva Biotechnology is a company that is creating a new method for producing biopharmaceuticals, chemicals, and biotech products using plants. Samabriva’s flexible platform combines the benefits of plant-based systems and traditional biomanufacturing techniques. By developing and cultivating high-yield plant clones in large-scale bioreactors it is possible to produce large quantities of high-value products more efficiently than traditional manufacturing methods.
Sona(UK) | $45,000,000 | (Apr 2, 2026)
Variance | $21,500,000 | (Apr 2, 2026)
TippingPoint Biosciences | $4,500,000 | (Apr 2, 2026)
Quantcore | $3,318,962 | (Apr 2, 2026)
Whirl AI | $8,900,000 | (Apr 2, 2026)
Semarion | $3,800,000 | (Apr 2, 2026)
Via Separations | $36,000,000 | (Apr 2, 2026)
Stedi | $50,000,000 | (Mar 31, 2026)